High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy

Clinical Cancer Research

Volumn 11, Issue 8, 2005, Pages 2894-2898

  Chang, Joe Y ^a   Komaki, Ritsuko ^a   Sasaki, Ryohei ^a,b   Liao, Zhongxing ^a   Stevens, Craig W ^a   Lu, Charles ^a   Fossella, Frank V ^a   Allen, Pamela K ^a   Cox, James D ^a   Spitz, Margaret R ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Kobe Graduate School of Medicine   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CISPLATIN; GEMCITABINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA STRAND BREAKAGE; FEMALE; GENE IDENTIFICATION; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUTAGENESIS; PERIPHERAL LYMPHOCYTE; PREDICTION; PRIORITY JOURNAL; RADIATION DOSE; SMOKING;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; BLEOMYCIN; CARCINOMA, NON-SMALL-CELL LUNG; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; MUTAGENS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 20244363386     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2176     Document Type: Article

References (22)

1. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc of ASCO 2003;22:621.
2. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000;92:874-97.
3. Wu X, Lippman SM, Lee JJ, et al. Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions. Cancer Res 2002;62:2813-8.
4. Spitz M, Lippman S, Jiang H, et al. Mutagen sensitivity as a predictor of tumor recurrence in patients with cancer of the upper aerodigestive tract. J Natl Cancer Inst 1998;90:243-5.
5. Zheng Y-L, Loffredo CA, Yu Z, et al. Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis 2003;24:269-74.
6. Lee JJ, Trizna Z, Hsu TC, Spitz MR, Hong WK. A statistical analysis of the reliability and classification error in application of the mutagen sensitivity assay. Cancer Epidemiol Biomarkers Prev 1996;5:191-7.
7. Salgia R, Skarin A. Molecular abnormalities in lung cancer. J Clin Oncol 1998;16:1207-17.
8. Lynch TJ, Bell DW Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
9. Hsu TC, Johnston DA, Cherry LM, et al. Sensitivity to genotoxic effects of bleomycin in humans: possible relationship to environmental carcinogenesis. Int J Cancer 1989;43:403-9.
10. Wu X, Zhao Y, Honn SE, et al. Benzo[a]pyrene diol epoxide-induced 3p21.3 aberrations and genetic predisposition to lung cancer. Cancer Res 1998;58:1605-8.
11. Bosken CH, Wei Q, Amos CI, Spitz MR. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 2002;94:1091-9.
12. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001;61:1354-7.
13. Lunn RM, Helzlsouer KJ, Parshad R, et al. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000;21:551-5.
14. Dianova II, Sleeth KM, Allinson SL, et al. XRCC1-DNA polymerase β interaction is required for efficient base excision repair. Nucleic Acids Res 2004;32:2550-5.
15. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004;22:2594-601.
16. Melton D, Ketchen A, Nunez F, et al. Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J Cell Sci 1998;111:395-4.
17. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004;10:4939-43.
18. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004;44:311-6.
19. Rosell R, Fossella F, Milas L, Group SLC. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer 2002;38:43-9.
20. Lord RVN, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
21. Rosell R, Taron M, Alberola V, Massuti B, Felip E. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003;41:S97-102.
22. Rosell R, Taron M, Camps C, Lopez-Vivanco G. Influence of genetic markers on survival in non-small-cell lung cancer. Drugs Today 2003;39:775-86.